1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Application due: October 17, 2024, 5:00 PM local time. Status: EXPIRED.
The Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials is a grant from the National Institutes of Health (NIH) that funds multi-site Phase Ib through Phase III clinical trials of interventions for Alzheimer's disease and related dementias. Approximately $10 million is available in the current fiscal year, with individual R01 budgets not subject to fixed limits.
Eligible applicants include higher education institutions, nonprofits with 501(c)(3) status, for-profit organizations including small businesses, government agencies, and foreign organizations. A critical requirement is that applicants must obtain prior approval from the ACTC steering committee at least five months before submission. The program supports adherence improvement, biomarker development, and novel therapeutic approaches.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
RFA-AG-25-010 - Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials (R01 Clinical Trial Required) is used for the submission of applications to the following Notices of Special Interest (NOSIs) | Grants & Funding U.S. Department of Health and Human Services National Institutes of Health RFA-AG-25-010 - Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials (R01 Clinical Trial Required) is used for the
submission of applications to the following Notices of Special Interest (NOSIs) Notice of Special Interest (NOSI): Improving Adherence to Treatment and Prevention Regimens and Maintenance of Health Behaviors to Promote Health OBSSR, NCCIH, NCI, NEI, NHLBI, NIA, NIDA, NIMH, NIMHD, NINR, OAR, ODP, ORWH P01, P30, R01, R03, UG3/UH3, R34, U24, R41/R42, R21, R43/R44, R21/R33, R61 Notice of Special Interest:
Development of Radiotracers for Diagnosis and Clinical Studies in Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) R43/R44, R41/R42, R01, U01, R21 For technical issues E-mail OER Webmaster
Portal login or registration may be required to access the full application.
According to the current listing, eligibility includes: Higher education institutions (public/private), nonprofits with 501(c)(3), for-profit organizations including small businesses, government agencies, foreign organizations. CRITICAL: Must have prior approval from ACTC steering committee (minimum 5 months advance notice). Confirm the full requirements in the official notice before applying.
The current listing shows approximately $10,000,000 available (FY2025); individual R01 budgets not limited. Verify award ceilings, matching requirements, and allowable costs in the official notice.
The published deadline was October 17, 2024, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials is funded by National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly. Note that portal registration or login may be required before you can access the full application.
The solicitation lists 4 required documents: ACTC steering committee approval letter, SAM registration, eRA Commons registration, and ClinicalTrials.gov registration. Check the official notice for formatting and page-limit rules.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article